

SNX8 RABBIT PAB

货号: S217845

产品全名: SNX8 兔多抗

基因符号: Mvpl

UNIPROT ID: Q9Y5X2 (Gene Accession - BC021565)

背景: Sorting nexin (SNX) proteins are members of a large family of hydrophilic PX (phospholipid-binding motif) domain-containing proteins that interact with a variety of receptor types. SNXs are widely expressed, although the tissue distribution of each SNX mRNA varies. The ability of SNXs to bind specific phospholipids, as well as their tendency to form protein-protein complexes, suggests a role for these proteins in cellular membrane trafficking and protein sorting. SNXs may also function specifically in pro-degradative sorting, internalization, endosomal recycling or simply in endosomal sorting. SNXs partially associate with cellular membranes, despite their hydrophilic nature. SNX8 is an ortholog of a yeast protein.

抗原: Fusion protein of human SNX8

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human esophagus cancer tissue using 217845(SNX8 Antibody) at a dilution of 1/30(Cytoplasm and Nucleus).



In comparison with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with the fusion protein and then with 217845(Anti-SNX8 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using 217845(Anti-SNX8 Antibody) at a dilution of 1/30.



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with fusion protein and then with D223204(Anti-SNX8 Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
